| review article | Q7318358 |
| scholarly article | Q13442814 |
| P8150 | COVIDWHO ID | covidwho-72377 |
| P6179 | Dimensions Publication ID | 1126723778 |
| P356 | DOI | 10.1016/J.CJCA.2020.04.010 |
| P932 | PMC publication ID | 7162773 |
| P698 | PubMed publication ID | 32439306 |
| P8299 | Semantic Scholar corpus ID | 215790274 |
| P2093 | author name string | Christopher Chang | |
| Feng Cao | |||
| Peng Hu | |||
| Taijiao Jiang | |||
| Guogang Xu | |||
| Qinyong Hu | |||
| Runsheng Wang | |||
| Lei Tu | |||
| Jinlyu Sun | |||
| Fujun Peng | |||
| Yongshi Yan | |||
| P2860 | cites work | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro | Q84360011 |
| A pneumonia outbreak associated with a new coronavirus of probable bat origin | Q84367633 | ||
| Consequences of hyperoxia and the toxicity of oxygen in the lung | Q21296803 | ||
| The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis | Q27001157 | ||
| Acute respiratory distress syndrome: the Berlin Definition | Q29615138 | ||
| Prone positioning in severe acute respiratory distress syndrome | Q34036811 | ||
| A Multicenter Retrospective Review of Prone Position Ventilation (PPV) in Treatment of Severe Human H7N9 Avian Flu. | Q35758904 | ||
| Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans | Q36757686 | ||
| Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure | Q46761231 | ||
| Mechanical Ventilation in Adults with Acute Respiratory Distress Syndrome. Summary of the Experimental Evidence for the Clinical Practice Guideline. | Q47751469 | ||
| Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China | Q83767469 | ||
| Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany | Q84106604 | ||
| Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? | Q95654335 | ||
| Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China | Q84574466 | ||
| Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury | Q84649317 | ||
| Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies | Q86824600 | ||
| Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study | Q87191917 | ||
| Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records | Q87281412 | ||
| Pathological findings of COVID-19 associated with acute respiratory distress syndrome | Q87281430 | ||
| COVID-19: too little, too late? | Q87407269 | ||
| Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study | Q87412594 | ||
| [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China] | Q87461543 | ||
| Critical care management of adults with community-acquired severe respiratory viral infection | Q87461636 | ||
| What to do next to control the 2019-nCoV epidemic? | Q87461659 | ||
| Discovering drugs to treat coronavirus disease 2019 (COVID-19) | Q87963364 | ||
| A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | Q88370045 | ||
| Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation | Q89108866 | ||
| Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China | Q89606309 | ||
| Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series | Q89787863 | ||
| Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China | Q89796088 | ||
| Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention | Q89855853 | ||
| Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2 | Q89913095 | ||
| Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study | Q89916803 | ||
| Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis | Q89931519 | ||
| Clinical Characteristics of Coronavirus Disease 2019 in China | Q89934806 | ||
| Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer | Q89956306 | ||
| On the use of corticosteroids for 2019-nCoV pneumonia | Q89981025 | ||
| Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools | Q89993478 | ||
| Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial | Q90156311 | ||
| In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Q90160332 | ||
| [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia] | Q90268489 | ||
| [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia] | Q90268493 | ||
| Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro | Q90482548 | ||
| COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression | Q90496530 | ||
| Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia | Q90502868 | ||
| Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak | Q90784309 | ||
| [Expert consensus on principal of clinical management of patients with severe emergent cardiovascular diseases during the epidemic period of COVID-19] | Q90797534 | ||
| An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China | Q90802726 | ||
| Experiences and lesson strategies for cardiology from the COVID-19 outbreak in Wuhan, China, by 'on the scene' cardiologists | Q91528665 | ||
| Fangcang shelter hospitals: a novel concept for responding to public health emergencies | Q91565164 | ||
| [Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019] | Q91849775 | ||
| Holistic care for patients with severe coronavirus disease 2019: An expert consensus | Q91944207 | ||
| Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection | Q91946162 | ||
| Drug treatment options for the 2019-new coronavirus (2019-nCoV) | Q93038127 | ||
| A multicenter RCT of noninvasive ventilation in pneumonia-induced early mild acute respiratory distress syndrome | Q93104168 | ||
| Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 | Q93221320 | ||
| Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China | Q94496849 | ||
| P921 | main subject | patient management | Q50283963 |
| COVID-19 | Q84263196 | ||
| P577 | publication date | 2020-04-17 | |
| 2020-06-01 | |||
| P1433 | published in | The Canadian Journal of Cardiology | Q3502278 |
| P1476 | title | Management and Treatment of COVID-19: The Chinese Experience |
| Q94446592 | A Focus on Covid-19: Fast and Accurate Information to Guide Management for Pandemic-Related Issues in Cardiac Patients |
| Q100427906 | COVID-19 patients managed in psychiatric inpatient settings due to first-episode mental disorders in Wuhan, China: clinical characteristics, treatments, outcomes, and our experiences |
| Q104738142 | Early management of critically ill patients with COVID-19 |
| Q98771821 | Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis |
| Q99624591 | Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial |
| Q96647411 | The Lessons and Experiences That Can Be Learned From China in Fighting Coronavirus Disease 2019 |
Search more.